Impact of Lofexidine on Stress, Craving and Opioid Use

Phase 2 Completed 112 enrolled Medical University of South Carolina National Institute on Drug Abuse (NIDA) · collab National Institutes of Health (NIH) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be randomly assigned to receive placebo or lofexidine for 5 weeks. At the end of five weeks, they will complete a human laboratory stress task and scripted opioid imagery task. Throughout the study a CREMA app (Cue Reactivity Ecological Momentary Assessment) will be used to monitor stress, craving and use in the natural environment.

Timeline

Start: 2019-06-26
Primary completion: 2024-01-30
Completion: 2024-01-30

Publications

Guille C, King C, Ramakrishnan V, Baker N, Cortese B, Nunn L, Rogers T, McRae-Clark A, Brady K. The impact of lofexidine on stress-related opioid craving and relapse: Design and methodology of a randomized clinical trial. Contemp Clin Trials. 2021 Dec;111:106616. doi: 10.1016/j.cct.2021.106616. Epub 2021 Nov 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lofexidine	Small molecule	0.72 mg	Oral

Impact of Lofexidine on Stress, Craving and Opioid Use

Summary

Timeline

Publications

Drugs

Indications